Overview

Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System With Askina Derm Overlay

Status:
Completed

Trial end date:
2006-07-01

Target enrollment:

Participant gender:

Summary

The objective of this study was primarily to investigate the bioequivalence and secondly to assess the wearability (adhesion) and acute irritation of Mylan fentanyl transdermal system with and without an overlay system following a single 25 µg/hr application worn for 72 hours.

Phase:

Phase 1

Details

Lead Sponsor:

Mylan Pharmaceuticals

Treatments:

Fentanyl